Patents by Inventor Charles H. Hannum

Charles H. Hannum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS
    Publication number: 20190127482
    Abstract: The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 2, 2019
    Inventors: Lawrence C. HOROWITZ, Ramesh R. BHATT, Charles H. HANNUM, Pamela K. FOREMAN, Danying CAI, Medini GORE, Li XU, Phil KOBEL
  • Surrogate binding proteins which bind DR4 and/or DR5
    Patent number: 9975956
    Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 22, 2018
    Assignee: i2 PHARMACEUTICALS, INC.
    Inventors: Arun K. Kashyap, Ramesh R. Bhatt, Michael Horowitz, Lawrence Horowitz, Sihong Zhou, Ryann E. O'Neil, Charles H. Hannum, Aaron L. Kurtzman, Li Xu
  • BINDING MOLECULE CONJUGATES
    Publication number: 20160354486
    Abstract: The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 8, 2016
    Inventors: Lawrence C. Horowitz, Ramesh R. Bhatt, Charles H. Hannum, Pamela K. Foreman, Danying Cai, Medini Gore, Li Xu, Phil Kobel
  • BINDING MOLECULE CONJUGATES
    Publication number: 20150011736
    Abstract: The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 8, 2015
    Inventors: Lawrence C. Horowitz, Ramesh R. Bhatt, Charles H. Hannum, Pamela K. Foreman, Danying Cai, Medini Gore, Li Xu, Phil Kobel
  • SURROGATE BINDING PROTEINS
    Publication number: 20150004162
    Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Inventors: Arun K. Kashyap, Ramesh R. Bhatt, Michael Horowitz, Lawrence Horowitz, Sihong Zhou, Ryann E. O'Neil, Charles H. Hannum, Aaron L. Kurtzman, Li Xu
  • Antibodies that bind purified mammalian FLT3 ligands
    Patent number: 7537932
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • Purified mammalian Flt3 ligands; agonists; antagonists
    Patent number: 7534867
    Abstract: Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 2009
    Assignees: Schering Corporation, Inserm
    Inventors: Charles H. Hannum, Janice A. Culpepper, Frank D. Lee, Daniel Birnbaum
  • Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
    Patent number: 6858409
    Abstract: Compounds are disclosed having the general formula R1—X—R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 22, 2005
    Assignees: Amgen Inc., The Regents of the University of Colorado
    Inventors: Robert C. Thompson, Charles H. Hannum, Stephen P. Eisenberg, William P. Arend, Fenneke G. Joslin, Andreas Sommer
  • Interleukin-1 inhibitors, compositions, and methods of treatment
    Patent number: 6599873
    Abstract: Interleukin-1 inhibitors are provided. Compositions comprising an interleukin-1 inhibitor are provided. Methods of treating a patient comprising administering an interleukin-1 inhibitor are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 29, 2003
    Assignees: Amgen Inc., The Regents of the University of Colorado
    Inventors: Andreas Sommer, Charles H. Hannum, Stephen P. Eisenburg, Robert C. Thompson, William P. Arend, Fenneke G. Joslin
  • Interleukin-1 inhibitors
    Patent number: 5075222
    Abstract: DNA sequences that encode Interleukin-1 inhibitors and recombinant-DNA methods for the production of interleukin-1 inhibitors are provided. The DNA sequences encode proteins having interleukin-1 inhibitors activity.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: December 24, 1991
    Assignee: Synergen, Inc.
    Inventors: Charles H. Hannum, Stephen P. Eisenburg, Robert C. Thompson, William P. Arend, Fenneke G. Joslin